Valuation: Cingulate Inc.

Market Cap 59.67M 52.16M 48.23M 44.26M 83.77M 5.75B 85.22M 575M 226M 2.81B 224M 219M 9.69B P/E 2026 *
-1.89x
P/E 2027 * -4.41x
Enterprise Value 59.67M 52.16M 48.23M 44.26M 83.77M 5.75B 85.22M 575M 226M 2.81B 224M 219M 9.69B EV / Sales 2026 *
20.6x
EV / Sales 2027 * 2.98x
Free-Float
69.46%
Yield 2026 *
-
Yield 2027 * -
1 day-3.49%
1 week-10.51%
Current month-19.01%
1 month-6.54%
3 months-15.78%
6 months-21.03%
Current year+2.07%
1 week 4.34
Extreme 4.335
4.9
1 month 4.34
Extreme 4.335
6.04
Current year 3.16
Extreme 3.16
11.89
1 year 3.16
Extreme 3.16
11.89
3 years 1.8
Extreme 1.8001
196.73
5 years 1.8
Extreme 1.8001
1,236
10 years 1.8
Extreme 1.8001
1,236
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 2017-12-31
Chief Tech/Sci/R&D Officer 69 2017-12-31
Chief Executive Officer 51 2012-04-30
Director TitleAgeSince
Director/Board Member 87 2018-05-31
Director/Board Member 59 2018-05-31
Chairman 51 2012-04-30
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Founder

3,885 0.0288%
3/31/26 Free

Founder

3,422 0.0442%
3/9/26 Free

Founder

5,551 0.0717%
Change 5-day change 1-year change 3-year change Capi.($)
-3.49%-10.51%-6.14%-97.66% 59.67M
-0.14%-2.22%+0.53%+5.88% 49.7B
-2.85%-6.25%+366.61%+572.09% 38.09B
+1.98%+4.82%+13.71%+61.68% 35.29B
+1.78%+0.73%+32.68%-4.80% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
-3.27%-5.67% - - 16.14B
+1.64%+0.45%+70.86%+121.18% 15.36B
+1.15%+1.94%+15.93%+19.68% 13.89B
-1.21%+0.73%+18.02%-30.96% 13.02B
Average -0.44%-1.56%+57.40%+74.94% 24.39B
Weighted average by Cap. -0.04%-0.65%+75.90%+116.63%

Financials

2026 *2027 *
Net sales 2.89M 2.53M 2.34M 2.15M 4.06M 279M 4.13M 27.9M 10.96M 136M 10.87M 10.63M 470M 20.04M 17.51M 16.2M 14.86M 28.13M 1.93B 28.62M 193M 75.88M 943M 75.24M 73.59M 3.25B
Net income -29.32M -25.63M -23.7M -21.75M -41.17M -2.83B -41.88M -283M -111M -1.38B -110M -108M -4.76B -13.31M -11.64M -10.76M -9.87M -18.69M -1.28B -19.01M -128M -50.42M -626M -49.99M -48.9M -2.16B
Net Debt - -
Logo Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Employees
14
Date Price Change Volume
26-07-16 US$4.430 -3.49% 323,232
26-07-15 US$4.590 -2.55% 210,445
26-07-14 US$4.710 +0.64% 205,285
26-07-13 US$4.680 -4.68% 346,104
26-07-10 US$4.910 -0.81% 276,886
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.430USD
Average target price
23.00USD
Spread / Average Target
+419.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CING Stock